Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has entered into a supply agreement with PharmaAla Biotech Holdings Inc to obtain their LaNeo, GMP source of 3,4-Methylenedioxymethamphetamine (MDMA) for the development of Revive’s microneedle patch delivery system.
On February 3, Revive announced a research collaboration with PharmaTher Holdings Ltd to evaluate the microneedle patch technology with MDMA.
In a statement, the company noted that PharmaAla is the first publicly traded company to manufacture GMP MDMA and the first company to make two clinical-grade psychedelic APIs available to customers.
READ: Revive Therapeutics enters into research collaboration agreement with PharmaTher to develop MDMA transdermal patch
Further, it is the only publicly traded company to have completed manufacturing of GMP MDMA and is a registered supplier to customers on three different continents, Revive noted.
“Securing the supply of MDMA from PharmAla allows us to confidently advance our upcoming product and clinical development plans with our MDMA microneedle patch for mental health and abuse disorders," commented Revive CEO Michael Frank.
PharmaAla CEO Nick Kadysh noted that as countries like Australia move to allow the use of MDMA as a therapeutic molecule for the treatment of mental health disorders like post-traumatic stress disorder (PTSD), new drug product forms will be crucial.
“We’re proud to be able to offer our engineering MDMA to Revive in their development of an MDMA microneedle patch, and to ultimately supply them with LaNeo GMP MDMA as their development accelerates into human use,” Kadysh said.
PharmAla is a biotechnology company focused on researching, developing, and manufacturing MDXX-class molecules, including MDMA.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the US Food and Drug Administration (FDA) such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie